Hughes DA - Search Results

1

Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher disease.

Reed MC, Schiffer C, Heales S, Mehta AB, Hughes DA. Reed MC, et al. Among authors: hughes da. Mol Genet Metab. 2018 Aug;124(4):278-286. doi: 10.1016/j.ymgme.2018.06.007. Epub 2018 Jun 14. Mol Genet Metab. 2018. PMID: 29934064

2

Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.

Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM. Shah JS, et al. Among authors: hughes da. Am J Cardiol. 2005 Sep 15;96(6):842-6. doi: 10.1016/j.amjcard.2005.05.033. Am J Cardiol. 2005. PMID: 16169374

3

The role of heparin in alleviating complement-mediated acute intravascular haemolysis.

Mannari D, Liu C, Hughes D, Mehta A. Mannari D, et al. Acta Haematol. 2008;119(3):166-8. doi: 10.1159/000134221. Epub 2008 May 21. Acta Haematol. 2008. PMID: 18493118

4

The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy.

Kounas S, Demetrescu C, Pantazis AA, Keren A, Lee PJ, Hughes D, Mehta A, Elliott PM. Kounas S, et al. J Am Coll Cardiol. 2008 May 27;51(21):2058-61. doi: 10.1016/j.jacc.2008.02.046. J Am Coll Cardiol. 2008. PMID: 18498962 Free article.

5

Enzyme, substrate, and myeloma in Gaucher disease.

Hughes DA. Hughes DA. Am J Hematol. 2009 Apr;84(4):199-201. doi: 10.1002/ajh.21375. Am J Hematol. 2009. PMID: 19291728 Free article. No abstract available.

6

Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).

Linthorst GE, Germain DP, Hollak CE, Hughes D, Rolfs A, Wanner C, Mehta A; European Medicines Agency. Linthorst GE, et al. Mol Genet Metab. 2011 Jan;102(1):99-102. doi: 10.1016/j.ymgme.2010.11.155. Epub 2010 Nov 30. Mol Genet Metab. 2011. PMID: 21123099

7

Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy.

Deegan PB, Pavlova E, Tindall J, Stein PE, Bearcroft P, Mehta A, Hughes D, Wraith JE, Cox TM. Deegan PB, et al. Medicine (Baltimore). 2011 Jan;90(1):52-60. doi: 10.1097/MD.0b013e3182057be4. Medicine (Baltimore). 2011. PMID: 21200186 Free article.

8

Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey.

Hughes DA, Barba Romero MÁ, Hollak CE, Giugliani R, Deegan PB. Hughes DA, et al. Mol Genet Metab. 2011 Jul;103(3):207-14. doi: 10.1016/j.ymgme.2011.03.022. Epub 2011 Mar 31. Mol Genet Metab. 2011. PMID: 21543245 Clinical Trial.

9

Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease.

O'Mahony C, Coats C, Cardona M, Garcia A, Calcagnino M, Murphy E, Lachmann R, Mehta A, Hughes D, Elliott PM. O'Mahony C, et al. Europace. 2011 Dec;13(12):1781-8. doi: 10.1093/europace/eur267. Epub 2011 Aug 18. Europace. 2011. PMID: 21856674

10

Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey.

Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB, Hughes DA; ACES study group. Elliott P, et al. Among authors: hughes da. Heart. 2011 Dec;97(23):1957-60. doi: 10.1136/heartjnl-2011-300364. Epub 2011 Sep 2. Heart. 2011. PMID: 21890869

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

528 results

Search Page

Filters